Journey Medical (DERM) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7$12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update Scottsdal ...